Study guide
14.4 Electrooculogram (EOG), Arden Ratio & RPE Light Peak Dynamics
IJCAHPO Certified Ophthalmic Medical Technologist COMT
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The COMT Examination, Eligibility & Certification Requirements
1.1 The 190-Question Multiple-Choice Examination & the 22 Official Content Areas 1.2 The COT Skill Evaluation & the COMT Performance Test 1.3 Eligibility Pathways, Fees, Timelines & Recertification
2 Chapter 2: General Medical Knowledge I — Ocular Anatomy & Physiology
2.1 Orbit, Eyelids, Lacrimal System, Conjunctiva & Extraocular Muscles 2.2 Cornea, Sclera, Anterior Chamber, Angle, Aqueous Dynamics & Crystalline Lens 2.3 Uvea, Retina, Vitreous, Optic Nerve, Ocular Circulation & the Visual Pathway
3 Chapter 3: General Medical Knowledge II — Eye Disease, Systemic Manifestations, Terminology & Safety
3.1 Frequently Encountered Eye Conditions by Structure & Inflammation Versus Infection 3.2 Body Systems & the Ocular Manifestations of Systemic Disease 3.3 Medical Terminology, Approved Abbreviations, Hazardous Waste & Clinic Safety
4 Chapter 4: Ophthalmic History Taking & Clinical Documentation
4.1 The Five History Domains: Ocular, Medical, Medication, Social & Family 4.2 Charting Conventions, Scribing & the Electronic Medical Record
5 Chapter 5: Visual Assessment, Accommodative Testing & Low Vision
5.1 Measuring Acuity at Every Level & in Preliterate, Illiterate and Non-Verbal Patients 5.2 Stereoacuity, Near Point of Accommodation, Near Point of Convergence & the AC/A Ratio 5.3 Low Vision Assessment, Magnification Calculation & Device Instruction
6 Chapter 6: Tonometry, Keratometry & Pupil Measurement
6.1 Goldmann Applanation Tonometry: Technique, Sources of Error & the Imbert-Fick Principle 6.2 Hand-Held Applanators, Non-Contact Tonometry, Rebound Tonometry & Disinfection 6.3 Manual & Automated Keratometry: Technique, Readings and Interpretation 6.4 Pupil Measurement, Shape, Reactivity & Evaluating Anisocoria
7 Chapter 7: Lensometry, Spectacle Optics & Prescription Analysis
7.1 Manual Lensometry: Eyepiece Focus, Neutralising Sphere, Cylinder & Axis 7.2 Neutralising Reading Adds: Bifocal, Trifocal, Progressive & Determining the Near Add 7.3 Identifying & Measuring Prism: Ground-In, Decentration, Fresnel Press-On & Slab-Off 7.4 Transposition, Spherical Equivalent, Vertex Distance & Prescription Components 7.5 The Geneva Lens Clock, Lens Materials, Progressive Markings & Spectacle Adjustment
8 Chapter 8: Refraction, Retinoscopy & Refinement
8.1 Autorefraction, Refractive Error Types & Establishing an Objective Starting Point 8.2 Streak Retinoscopy: With Motion, Against Motion, Neutralisation & Working Distance 8.3 Subjective Refinement: Fogging, Jackson Cross Cylinder, Duochrome & Binocular Balance 8.4 Near Add Determination, Vertex Recording & Refraction in Difficult Situations
9 Chapter 9: Ocular Motility, Strabismus & Advanced Optics
9.1 Ocular Kinematics: Ductions, Versions, Vergences, Hering's & Sherrington's Laws 9.2 Quantitative Strabismus Measurements: Alternate Cover Test, Prism Cover Test & Lancaster Red-Green / Hess Screen 9.3 Cranial Nerve Palsies (CN III, IV, VI), Restrictive Myopathies & Forced Duction Testing 9.4 Clinical Optics, Prentice's Rule, Slab-Off Prisms & Wavefront Aberrations
10 Chapter 10: Sensory Fusion Testing, Nystagmus, Amblyopia & Vergence Therapy
10.1 Sensory Fusion Testing: Worth 4-Dot, Maddox Rod & Bagolini Lenses 10.2 Hirschberg, Krimsky, Brückner & Fusional Vergence Amplitudes 10.3 Nystagmus, Amblyopia Therapy & Convergence Training
11 Chapter 11: Advanced Visual Fields & Neuro-Ophthalmic Evaluation
11.1 Amsler Grid & Confrontation Visual Field Testing 11.2 Automated Static Perimetry: HFA Strategies (SITA Standard, SITA Fast), Reliability Indices & Statpac Analysis 11.3 Visual Field Defect Patterns: Glaucomatous Nerve Fiber Bundle Deficits vs. Retinal Pathology 11.4 Kinetic Perimetry (Goldmann Perimetry) & Neurological Visual Pathway Defect Localization 11.5 Pupillary Pathways, RAPD Quantitation with Neutral Density Filters & Pharmacologic Testing
12 Chapter 12: Supplemental Testing — Glare, PAM, Colour Vision, Tear Film & Slit Lamp Technique
12.1 Glare Testing, Potential Acuity Meter & Contrast Sensitivity 12.2 Colour Vision: Pseudoisochromatic Plates, Farnsworth-Munsell D-15 & the 100-Hue Test 12.3 Tear Film Assessment: Schirmer, Tear Break-Up Time, Vital Dyes & Corneal Sensitivity 12.4 Slit Lamp Technique, Slit Lamp Lenses, Direct Ophthalmoscopy & Pen Light Examination 12.5 Exophthalmometry, Head & Posture Assessment and Wavefront Diagnostics
13 Chapter 13: Full-Field Electroretinography & ISCEV Protocols
13.1 Retinal Neurophysiology & Electrophysiologic Origin of Waveforms 13.2 ISCEV Standard Full-Field ERG Protocol & Electrode Systems 13.3 Dark-Adapted (Scotopic) Testing: Rod-Driven Responses & Combined Maximal Response 13.4 Light-Adapted (Photopic) Testing: Cone Response, 30-Hz Flicker & Oscillatory Potentials
14 Chapter 14: Advanced Electrophysiologic Testing (mfERG, PERG, VEP, EOG)
14.1 Multifocal Electroretinogram (mfERG): Topographic Retinal Mapping 14.2 Pattern Electroretinogram (PERG): Ganglion Cell & Macular Function 14.3 Visual Evoked Potentials (VEP): Flash, Pattern & Visual Pathway Integrity 14.4 Electrooculogram (EOG), Arden Ratio & RPE Light Peak Dynamics
15 Chapter 15: Fluorescein Angiography Principles & Technique
15.1 Fluorescein Angiography Principles, Exciter/Barrier Filters & Injection Protocol 15.2 Normal Transit Phases & Retinal/Choroidal Circulation Hemodynamics 15.3 Adverse Reactions, Patient Safety & Emergency Management
16 Chapter 16: Angiographic Interpretation & Pathology
16.1 Hyperfluorescence Mechanisms: Leakage, Staining, Pooling, Window Defects & Autofluorescence 16.2 Hypofluorescence Mechanisms: Vascular Non-Perfusion & Blocking Defects 16.3 Indocyanine Green (ICG) Angiography: Principles, Indications & Choroidal Pathology
17 Chapter 17: Advanced Fundus Imaging & Optical Coherence Tomography
17.1 Fundus Autofluorescence (FAF) & Ultra-Widefield Fundus Imaging 17.2 Spectral-Domain and Swept-Source OCT: Retinal Layer Architecture & Quantitative Analysis 17.3 Enhanced Depth Imaging (EDI-OCT) & Anterior Segment OCT (AS-OCT) 17.4 Optical Coherence Tomography Angiography (OCTA): Chorioretinal Plexuses & Biomarkers
18 Chapter 18: Ophthalmic Photography & Videography
18.1 The Fundus Camera: Optics, Alignment & Correcting Artefacts 18.2 Standard Fundus Photography: ETDRS Fields, Stereo Pairs, Red-Free & Wide-Field Imaging 18.3 Slit Lamp & Anterior Segment Photography 18.4 External Photography, Nine-Gaze Motility Documentation & Image Management
19 Chapter 19: Ophthalmic Echography (A-Scan, B-Scan & UBM)
19.1 Physics of Ophthalmic Ultrasound, Acoustic Impedance & Probe Transducers 19.2 Standardized Diagnostic A-Scan: Acoustic Spikes, Tissue Reflectivity & Attenuation 19.3 Diagnostic B-Scan Echography: Topographic, Kinetic & Quantitative Vitreoretinal Evaluation 19.4 Ultrasound Biomicroscopy (UBM): Anterior Segment Anatomy, Angle Pathology & Ciliary Body Imaging
20 Chapter 20: Biometry, Topography & Corneal Analysis
20.1 Optical Biometry vs. Immersion/Contact Ultrasound Biometry 20.2 Intraocular Lens (IOL) Power Calculation Formulas & Post-Refractive Adjustments 20.3 Corneal Topography, Scheimpflug Tomography & Keratoconus Screening 20.4 Corneal Pachymetry, Endothelial Specular Microscopy & Anterior Chamber Depth
21 Chapter 21: Rigid Gas Permeable & Specialty Lens Fitting
21.1 Rigid Gas Permeable (RGP) Material Properties, Dk/t & Oxygen Permeability 21.2 RGP Base Curve Selection, Diagnostic Fitting & Fluorescein Pattern Evaluation 21.3 Scleral Contact Lens Design, Sagittal Depth Fitting & Clearance Evaluation 21.4 Keratoconus, Irregular Corneas & Hybrid Contact Lens Systems
22 Chapter 22: Toric, Multifocal, Therapeutic Lenses & Complications
22.1 Toric Soft Contact Lens Dynamics, Stabilization Techniques & LARS Rule 22.2 Presbyopic & Multifocal Contact Lens Systems: Simultaneous vs. Translating Designs 22.3 Therapeutic Bandage Contact Lenses, Amniotic Membranes & Orthokeratology 22.4 Contact Lens-Induced Pathology, Giant Papillary Conjunctivitis & Infectious Keratitis
23 Chapter 23: Ocular Pharmacology
23.1 Routes of Drug Delivery, Prescription Components & Instillation Technique 23.2 Mydriatics, Cycloplegics, Anaesthetics & Diagnostic Agents 23.3 Glaucoma Medications: Classes, Mechanisms & Side Effects 23.4 Anti-Infectives, Corticosteroids, NSAIDs, Allergy Agents, Lubricants, Supplements & Anti-VEGF
24 Chapter 24: Microbiology & Ocular Specimen Collection
24.1 Types of Microorganisms & Pathways of Disease Transmission 24.2 Assisting with Conjunctival & Corneal Specimen Collection
25 Chapter 25: Anterior Segment, Glaucoma & Refractive Surgery
25.1 Advanced Phacoemulsification, Surgical Steps, Fluidics & Complication Management 25.2 Premium Intraocular Lenses: Toric, Multifocal, EDOF & Lens Exchange 25.3 Glaucoma Surgical Procedures: Trabeculectomy, Aqueous Shunts & MIGS Devices 25.4 Laser In Situ Keratomileusis (LASIK), PRK, SMILE & Phakic IOLs
26 Chapter 26: Vitreoretinal, Corneal & Trauma Surgery
26.1 Pars Plana Vitrectomy (PPV), Scleral Buckling & Intraocular Tamponades (Gas/Silicone Oil) 26.2 Corneal Transplantation: Penetrating Keratoplasty (PKP) & Lamellar Keratoplasty (DSAEK, DMEK, DALK) 26.3 Ocular Trauma Repair: Open Globe Management, Hyphema, Vitreous Loss & Endophthalmitis Protocol
27 Chapter 27: Surgical Asepsis, Instrumentation & Laser Procedures
27.1 Operating Room Sterilization, Aseptic Field Maintenance & Universal Precautions 27.2 Microsurgical Instrumentation, Maintenance & Sharps Safety 27.3 Ophthalmic Laser Physics, Delivery Systems & Safety (Nd:YAG, Argon/FD-Nd:YAG, SLT)
28 Chapter 28: Ophthalmic Patient Services & Education
28.1 Communicating with Patients, Families and Colleagues, and Handling Dissatisfaction 28.2 Patient Education & Counselling on Conditions, Medications, Tests and Results 28.3 Ophthalmic Emergencies, First Aid, Vital Signs & CPR 28.4 Triage, Urgency-Based Scheduling, Patient Flow & Telephone Management 28.5 Dressings and Shields, Prosthetics, Legal Forms, Referrals & Reimbursement Support
29 Chapter 29: Clinic Operations — Equipment Maintenance, Ethics, Coding & Compliance
29.1 Equipment Maintenance, Calibration, Emergency Equipment & Inventory 29.2 Confidentiality, Informed Consent, Scope of Practice & Ethical Standards 29.3 Coding, Scribing Compliance, Quality Assurance & Regulatory Requirements
14.4 Electrooculogram (EOG), Arden Ratio & RPE Light Peak Dynamics
Key Takeaways Explain This Topic AI
The electrooculogram (EOG) assesses the transepithelial standing potential (typically +6 to +10 mV) of the eye generated by the retinal pigment epithelium (RPE), driven by interactions with overlying photoreceptors.
The Arden Ratio is calculated as the Light Peak amplitude divided by the Dark Trough amplitude: normal is >1.85 (>185%), borderline is 1.65 to 1.85, and abnormal is <1.65 (<165%).
Best vitelliform macular dystrophy (BEST1 mutation) exhibits a pathognomonic flat EOG (Arden ratio 1.0–1.2) with a completely normal full-field ERG, present across all phenotypic stages and in asymptomatic carriers.
In adult-onset vitelliform macular dystrophy (AVMD / pattern dystrophy), the EOG is typically normal or only mildly subnormal, differentiating it clinically and genetically from Best disease.
The testing protocol requires skin electrodes at the inner and outer canthi, 15 minutes of dark adaptation to determine the Dark Trough, followed by 15 minutes of Ganzfeld light adaptation (100 cd/m²) to capture the Light Peak at 7–12 minutes.
Last updated: September 2026
Electrooculogram (EOG), Arden Ratio & RPE Light Peak Dynamics
Core Clinical Mandate: While the electroretinogram (ERG) measures rapid, millisecond-scale electrical potentials triggered by light, the electrooculogram (EOG) evaluates the slow, minutes-long metabolic dynamics of the retinal pigment epithelium (RPE) and its functional interaction with the photoreceptor layer. The hallmark clinical value of the EOG lies in calculating the Arden Ratio , which provides the pathognomonic diagnostic confirmation of Best vitelliform macular dystrophy .
- Biophysical Basis of the Ocular Standing Potential
- The Corneo-Fundal Standing Potential
The human eye functions as an electrical dipole:
Electrical Polarity: The anterior pole of the eye (the cornea) is electrically positive , and the posterior pole (the fundus / RPE-Bruch's complex) is electrically negative .
Resting Magnitude: This permanent, direct-current (DC) standing potential has a baseline magnitude of approximately +6 to +10 millivolts (mV) .
Cellular Generator: The standing potential is generated primarily by the transepithelial potential (TEP) of the retinal pigment epithelium (RPE). The RPE is a polarized cellular monolayer whose apical and basolateral membranes maintain unequal ionic permeabilities and active ion transport mechanisms (such as Na+/K+ ATPase and chloride transporters), establishing a continuous voltage gradient across the cell layer.
Loading diagram... Physiological Genesis of the Standing Potential and RPE Light Peak
Molecular Mechanisms: Bestrophin-1 and the Light Peak Genesis
The most clinically critical physiological property of the ocular standing potential is its dynamic, dramatic rise in response to steady illumination—the Light Peak :
The Photoreceptor-RPE Signaling Cascade
Dark Adaptation (The Dark Trough): When the eye is placed in complete darkness for 15 minutes, RPE transepithelial potential progressively declines, reaching a minimum steady-state baseline between 10 and 12 minutes termed the Dark Trough (DT) .
Light Adaptation: When a continuous Ganzfeld background light (100 cd/m²) is switched on, rod photoreceptors absorb photons and hyperpolarize.
The Chemical Messenger: Light-induced rod hyperpolarization decreases extracellular potassium [ K + ] [K^+] [ K + ] in the subretinal space, causing an initial hyperpolarization of the apical RPE membrane (which generates the c-wave of the flash ERG). Over several minutes, an elusive chemical messenger (involving intracellular calcium release) diffuses from the photoreceptors across the RPE cytoplasm to the basolateral membrane .
Bestrophin-1 Activation: The basolateral RPE membrane contains transmembrane calcium-activated chloride channels encoded by the BEST1 gene (historically called VMD2 ), known as bestrophin-1 .
Depolarization and Light Peak: Inflow of calcium opens bestrophin-1 channels, allowing chloride efflux. This selectively depolarizes the basolateral membrane , causing a massive, slow surge in the transepithelial potential that reaches its maximum between 7 and 12 minutes post-light onset. This crest is termed the Light Peak (LP) .
Clinical Significance: Generation of the light peak requires both structurally intact, functional rod photoreceptors (to initiate the light signal) AND a healthy, functioning RPE basolateral chloride transport apparatus (to generate the electrical surge).
Arden Ratio Diagnostic Interpretation Thresholds
Derivation and Quantitative Interpretation of the Arden Ratio
Because the absolute voltage of the standing potential varies significantly between individuals based on skull thickness, skin impedance, and axial eye length, raw microvolt values cannot be used for clinical diagnosis. In 1962, G.B. Arden established a normalized ratio that compares the maximum light response to the dark baseline:
The Arden Ratio Formula Arden Ratio = Light Peak Voltage ( μ V) Dark Trough Voltage ( μ V) \text{Arden Ratio} = \frac{\text{Light Peak Voltage (}\mu\text{V)}}{\text{Dark Trough Voltage (}\mu\text{V)}} Arden Ratio = Dark Trough Voltage ( μ V) Light Peak Voltage ( μ V)
Alternatively expressed as a percentage: Arden Index = ( Light Peak / Dark Trough ) × 100 % \text{Arden Index} = (\text{Light Peak} / \text{Dark Trough}) \times 100\% Arden Index = ( Light Peak / Dark Trough ) × 100% .
ISCEV Clinical Diagnostic Thresholds
Normal: Arden Ratio > 1.85 (or > 185%). In healthy young adults, the ratio typically ranges between 2.0 and 3.0.
Borderline / Subnormal: Arden Ratio 1.65 to 1.85 (165% to 185%). Requires repeat confirmation and clinical correlation.
Severely Abnormal: Arden Ratio < 1.65 (< 165%). Indicates widespread RPE or rod photoreceptor dysfunction.
Flat EOG (Extinguished Light Peak): Arden Ratio ~1.0 to 1.1 (100% to 110%). The light peak is completely absent; the standing potential remains completely flat despite continuous bright light stimulation. Arden Ratio Stratification:
- [ 1.0 ────── Flat ────── 1.1 ] ─── Abnormal ─── [ 1.65 ── Borderline ── 1.85 ] ─── Normal (>1.85) ──► 2.5+
- (Best Disease) (Healthy Eye)
- Clinical Hallmarks: Best Disease vs. Adult-Onset Vitelliform Maculopathy
- Best Vitelliform Macular Dystrophy (Best Disease)
Best disease is an autosomal dominant macular dystrophy caused by missense mutations in the BEST1 gene on chromosome 11q13:
The Pathognomonic Dissociation: The defining clinical hallmark of Best disease is a severely abnormal or flat EOG (Arden ratio typically 1.0 to 1.2) occurring in the presence of a completely normal full-field ERG (ffERG) .
Why ffERG is Normal: The mutation affects the chloride channels of the RPE throughout the fundus, but generalized photoreceptor function remains intact. Therefore, panretinal scotopic and photopic flash ERG a-waves and b-waves are completely normal.
Why EOG is Flat: Because bestrophin-1 chloride channels are defective, the RPE basolateral membrane cannot depolarize in response to rod signaling. The light peak is abolished.
Invariance Across Stages: The EOG is flat across every clinical stage of Best disease:
Stage 1 (Previtelliform): Normal macula or tiny punctate dots; EOG is already flat!
Stage 2 (Vitelliform / Egg-Yolk): Classic 1–2 mm yellow yolk-like lesion at the fovea; visual acuity typically 20/20 to 20/40; flat EOG.
Stage 3 (Pseudohypopyon): Partial resorption and settling of yellow lipofuscin-like fluid into a lower fluid level; flat EOG.
Stage 4 (Vitelliruptive / Scrambled Egg): Breakup and dispersion of vitelliform material; vision begins declining; flat EOG.
Stage 5 (Atrophic / Cicatricial): Fibrovascular scar, choroidal neovascularization (CNV), or geographic RPE atrophy; vision 20/200; flat EOG.
Detection of Asymptomatic Carriers: In families with Best disease, asymptomatic gene carriers who possess completely normal fundi and 20/20 visual acuity still exhibit a flat EOG. EOG is therefore an essential genetic counseling tool.
Differential Diagnosis: Best Disease vs. Adult-Onset Vitelliform Macular Dystrophy (AVMD)
A frequent board-exam dilemma involves distinguishing true juvenile Best disease from Adult-Onset Vitelliform Macular Dystrophy (AVMD / Pattern Dystrophy) :
- Clinical Parameter Best Vitelliform Macular Dystrophy Adult-Onset Vitelliform Maculopathy (AVMD)
- Age of Onset Childhood / Adolescence (typically 3–15 years) Middle age / Elderly (typically 40–70 years)
- Genetic Mutations BEST1 (chromosome 11q13) Most commonly PRPH2 (peripherin-2/RDS) or BEST1 (rarely)
Lesion Size Large (>1.0–2.0 mm, ~1 disc diameter), bright yellow Small (<0.5–1.0 mm, 1/3 to 1/2 disc diameter), often with central pigment spot
Full-Field ERG Completely Normal Completely Normal
Electrooculogram (EOG) Severely Abnormal / Flat (Arden Ratio 1.0 to 1.2) Normal to Mildly Subnormal (Arden Ratio > 1.65–1.80)
Visual Acuity Course Often remarkably preserved (20/20 to 20/40) despite dramatic egg-yolk appearance Mildly blurred or metamorphopsia; slowly progressive
Other Clinical Entities Affecting the EOG
Retinitis Pigmentosa (RP) and Rod-Cone Dystrophies: EOG is severely abnormal or flat. However, unlike Best disease, the full-field ERG is also profoundly abnormal or extinguished , reflecting widespread rod degeneration.
Stargardt Disease: EOG is usually subnormal to abnormal in advanced stages, accompanied by photopic ERG abnormalities and dark choroid on fluorescein angiography.
Chloroquine / Hydroxychloroquine Toxicity: Can depress the Arden ratio, but mfERG and SD-OCT detect early toxicity with far greater spatial specificity.
Technologist Instrumentation, Electrode Maintenance, and Saccadic Pacing
Unlike the ERG which requires corneal contact lenses or fibers, the EOG is recorded entirely using cutaneous (skin) electrodes that measure voltage changes as the eyes rotate back and forth.
1. Electrode Application: The Bicanthal Montage
Electrode Type: Matched, highly stable silver/silver chloride (Ag/AgCl) skin electrodes .
Electrode Placement:
Clean the skin at the inner and outer canthus of each eye with abrasive paste (NuPrep).
Place one electrode at the medial (inner) canthus and one at the lateral (outer) canthus of the tested eye, positioned as close as possible to the eyelid margins without contacting tears.
Place a ground electrode on the central forehead (Fpz) or earlobe.
Measurement Principle: As the eye makes horizontal saccades, the positive cornea moves closer to one electrode while the negative posterior pole moves closer to the other, creating a transient voltage swing proportional to the standing potential. Bicanthal Electrode Placement & Saccadic Voltage Generation:
- [ Medial Electrode (-) ] ──◄── [ EYE ] ──►── [ Lateral Electrode (+) ]
- ▲ ▲
- Gaze Left: Cornea nears Medial ──► Negative Voltage Deflection Recorded
- Gaze Right: Cornea nears Lateral ──► Positive Voltage Deflection Recorded
- Peak-to-Peak Amplitude = Voltage Swing proportional to Transepithelial Potential
- 2. Saccadic Pacing and Visual Angle Calibration
Fixation Targets: Two red LED fixation lamps situated inside a Ganzfeld dome or on an illuminated panel.
Saccadic Angle: The two fixation lights are separated by a visual angle of 30° (±15° from center fixation).
Pacing Rhythm: The LEDs alternate back and forth at a frequency of 1.0 to 1.5 Hz (one saccade every 0.7 to 1.0 seconds).
Sampling Interval: Under ISCEV standards, the patient does not track lights continuously for 30 minutes. Instead, the patient performs saccades for a 10- to 15-second sampling epoch once every 1 to 2 minutes throughout the test.
3. The 30-Minute Chronological Test Protocol
Pre-adaptation (15 minutes): Patient sits in ordinary room illumination to stabilize baseline retinal state.
Dark Adaptation Phase (15 minutes): Total darkness. Recording epochs are sampled every 1 to 2 minutes. The standing potential drops to reach the Dark Trough (DT) at approximately 10 to 12 minutes.
Light Adaptation Phase (15 minutes): Ganzfeld background light (100 cd/m²) is switched on. Recording epochs continue every 1 to 2 minutes. The potential surges to reach the Light Peak (LP) at approximately 7 to 12 minutes, followed by a damped downward oscillation.
4. Technical Pitfalls and Artifact Rejection
Incomplete / Undershooting Saccades: If the patient becomes fatigued, lazy, or distracted and fails to make full 30° saccades, the measured voltage swing will drop, producing a falsely low Arden ratio. The technologist must verbally encourage crisp, complete fixation jumps.
Head Movement: The patient's head must remain firmly stabilized in a chin rest; head rotations introduce huge baseline drifts.
Electrode Polarization: Use exclusively non-polarizable Ag/AgCl electrodes. Reusable electrodes must be thoroughly cleaned to prevent asymmetric DC drift.